GILD - GILEAD SCIENCES, INC.

147.83
-2.200   -1.488%

Share volume: 6,356,236
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$150.03
-2.20
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
90%
Profitability 100%
Dept financing 50%
Liquidity 53%
Performance 100%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.75%
1 Month
1.09%
3 Months
20.56%
6 Months
31.09%
1 Year
28.84%
2 Year
104.61%
Key data
Stock price
$147.83
P/E Ratio 
17.89
DAY RANGE
$145.52 - $148.84
EPS 
$6.84
52 WEEK RANGE
$93.37 - $157.29
52 WEEK CHANGE
$28.06
MARKET CAP 
152.281 B
YIELD 
2.57%
SHARES OUTSTANDING 
1.241 B
DIVIDEND
$0.82
EX-DIVIDEND DATE
03-13-2026
NEXT EARNINGS DATE
08-07-2025
BETA 
0.63
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,608,696
AVERAGE 30 VOLUME 
$7,805,066
Company detail
CEO: Daniel P. O'Day
Region: US
Website: gilead.com
Employees: 17,000
IPO year: 1992
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Gilead Sciences discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, and Atripla products for the treatment of HIV/AIDS.

Recent news